Effects of sparsentan, a dual endothelin receptor and angiotensin receptor blocker, on renal outcomes in patients with primary focal segmental glomerulosclerosis (FSGS)

Effects of sparsentan, a dual endothelin receptor and angiotensin receptor blocker, on renal outcomes in patients with primary focal segmental glomerulosclerosis (FSGS)

Brief description of study

The purpose of this research is to study use of an investigational drug in Focal Segmental Glomerulosclerosis (FSGS) which is a rare disease that affects the kidneys in both adults and children. Kidneys are important to your health because they filter waste materials such as salts, toxins and water out of the blood. The waste is passed out of your body as urine (pee). FSGS causes scarring in parts of the kidney that filter these waste materials, may allow protein to leak into the urine. The leaking protein is a condition called proteinuria and it causes fluid to build up in the body. If the protein leaks for too long, it can eventually lead to kidney failure (kidneys stop working).

Detailed description of study

The purpose of this study is to learn if Sparsentan is safe and effective in lowering the amount of protein in the urine. In this study, Sparsentan will be compared to a drug called Irbesartan, which is approved by the U.S. Food and Drug Administration (FDA), to treat high blood pressure and kidney disease caused by diabetes. Sometimes, it is also used to treat patients with proteinuria (high amount of protein in the urine). 

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    renal,FSGS,kidney
  • Age: Between 12 Years - 75 Years
  • Gender: All
Updated on 08 Jul 2023. Study ID: 831313

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center